Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ardeparin

Known as: ardeparin [Chemical/Ingredient] 
 
National Institutes of Health

Related topics

Related topics

11 relations

Broader (3)

AnticoagulantsFibrinolytic AgentsHeparin, Low-Molecular-Weight
Drug AllergyHemorrhagic DisordersPostoperative ComplicationsPulmonary Embolism
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
RETRACTED: Zonula occludens toxin synthetic peptide derivative AT1002 enhances in vitro and in vivo intestinal absorption of low molecular weight heparin
RETRACTED 
2006
2006
Evaluation of the oral bioavailability of low molecular weight heparin formulated with glycyrrhetinic acid as permeation enhancer
Low molecular weight heparin (LMWH) is the agent of choice for anticoagulant therapy and prophylaxis of thrombosis and coronary… Expand
2006
2006
Modulation of gastrointestinal permeability of low‐molecular‐weight heparin by L‐arginine: in‐vivo and in‐vitro evaluation
L‐Arginine is the principal physiological precursor of nitric oxide (NO, a key neurotransmitter) that plays a versatile role in… Expand
2005
2005
RETRACTED: Oral delivery of low-molecular-weight heparin using sodium caprate as absorption enhancer reaches therapeutic levels
RETRACTED 
1999
1999
Usefulness of subcutaneous low molecular weight heparin (ardeparin) for reduction of restenosis after percutaneous transluminal coronary angioplasty.
In addition to its anticoagulant effects, heparin is known to have antiproliferative effects on vascular smooth muscle cells… Expand
1999
1999
Low Molecular Weight Heparins: Differences and Similarities in Approved Preparations in the United States
  • R. Bick, J. Fareed
  • Clinical and applied thrombosis/hemostasis…
  • 1999
    • Corpus ID: 24581827
There is adequate preclinical data to support the differential biochemical and pharmacological behavior of the currently approved… Expand
  • figure 3
  • figure 1
  • figure 2
  • figure 4
  • figure 5
Highly Cited
1996
Highly Cited
1996
Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery.
BACKGROUND Deep vein thrombosis is common in patients undergoing major knee surgery. Static graduated compression stockings… Expand
Highly Cited
1995
Highly Cited
1995
The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria.
Osteoporosis is a well-recognized complication of long-term heparin use. However, the mechanisms by which heparin can influence… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
1995
1995
TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin.
Tissue factor pathway inhibitor (TFPI) is an important mediator of the in vivo anticoagulant/antithrombotic properties of… Expand
Highly Cited
1994
Highly Cited
1994
Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin.
We have compared the non-specific binding of unfractionated heparin (UFH) with that of low molecular weight heparin (LMWH) to… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE